Related Posts
Blue Jet Healthcare, a speciality pharmaceutical and healthcare ingredient company filed its draft red herring prospectus (DRHP) with Sebi on Monday for an initial public offer.
The public issue is entirely an offer-for-sale (OFS) of up to 21.7 million shares by the promoters and other shareholders to the tune of around ₹1,800 crore, said bankers.
The company operates under the “Blue Jet” brand offering niche products targeted at innovator pharmaceutical companies and multinational generic pharmaceutical companies.
The company, which is net debt free, reported a 37% jump in operational revenues for 2022 to ₹683.47 crore. Its profit after tax increased 33.73% in FY22 to ₹181.59 crore.
Capital, , and JP Morgan are the book-running lead managers.
Denial of responsibility! TechnoCodex is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.
